Objective: The Accelerating Medicines Partnership in Parkinson’s Disease (AMP PD; https://amp-pd.org) aims to identify and validate diagnostic, prognostic, and progression biomarkers for Parkinson’s Disease (PD).
Background: AMP PD is a public-private partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), industry (Celgene, GSK, Pfizer, Sanofi and Verily) and non-profit organizations (The Michael J. Fox Foundation for Parkinson’s Research [MJFF] and Aligning Science Across Parkinson’s [ASAP]).
Method: The AMP PD research plan encompasses molecular and longitudinal clinical profiling of patient data and biosamples with the goal of identifying and validating biomarkers for PD. It includes sharing of harmonized molecular (e.g. whole genome sequencing, transcriptomics) and clinical data to identify new targets, disease subtypes, and predictive markers for PD progression and prognosis. AMP PD uses well-characterized cohorts with biosamples and clinical data that were collected under comparable protocols. Seven unified cohorts are currently included in AMP PD and described here (https://amp-pd.org/unified-cohorts). Additional data will be added in 2021 from the ASAP Global Parkinson’s Genetics Program (GP2) and the NINDS Study of Urate Elevation in Parkinson’s Disease, Phase 3 (SURE-PD3) cohort. Data is hosted within the Google Cloud Platform to provide a secure and collaborative computing environment to access and analyze available data with shared tools and workspaces
Results: As of March 2021, AMP PD includes harmonized clinical data from 10,247 participants across 7 cohorts including 3,009 subjects with PD (807 with known mutations), 4,306 healthy control subjects (800 with known PD mutations), and 2,932 subjects with other diagnosis including Lewy Body Dementia or other related PDisms. There are 3,274 participants with longitudinal blood-based transcriptomics, and WGS data available from 9,901 subjects. Future datasets scheduled for release in 2021 will include proteomic analyses in plasma and cerebrospinal fluid.
Conclusion: AMP PD’s cloud infrastructure fosters sharing of tools and data, supports nimble data analysis, decreases storage and compute costs, and facilitates inter-institutional collaboration to enable the discovery of diagnostic, prognostic, and progression biomarkers for PD clinical trial design and therapeutic development.
To cite this abstract in AMA style:
C. Swanson-Fischer, E. Appelmans, D. Babcock, M. Bookman, D. Alonso, L. Kirsch, C. Wonders, J. Ward, S. Biswas, S. Dey, A. Singleton, H. Iwaki. AMP PD: Collaborating in the discovery of biomarkers to accelerate the development of therapies for Parkinson’s disease [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/amp-pd-collaborating-in-the-discovery-of-biomarkers-to-accelerate-the-development-of-therapies-for-parkinsons-disease/. Accessed November 24, 2024.« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/amp-pd-collaborating-in-the-discovery-of-biomarkers-to-accelerate-the-development-of-therapies-for-parkinsons-disease/